Thank you for your interest in Boehringer Ingelheim's activities in oncology.
If you have questions or comments, please use this contact form to send us a message.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.